Consequently, pregnant women are tested for GBS infection and intrapartum antibiotic prophylaxis is administered to women who test positive for GBS. Although this is a successful strategy to prevent GBS transmission to the neonate during labor and delivery, in utero infections that occur earlier in pregnancy are not targeted by this approach.
Furthermore, the mechanisms of in utero infection remain unknown. Lakshmi Rajagopal. The Rajagopal laboratory is studying the molecular mechanisms and virulence factors utilized by GBS to adapt to various environmental niches, with the goal of developing additional strategies to prevent GBS infections.
Page last reviewed: 12 March Next review due: 12 March Group B strep. Group B strep is a type of bacteria called streptococcal bacteria. Group B strep is normally harmless and most people will not realise they have it. It's usually only a problem if it affects: pregnant woman — it could spread to the baby young babies — it can make them very ill elderly people or those who are already very ill — it can cause repeated or serious infections This page focuses on group B strep in pregnancy and babies.
Group B strep in pregnancy Group B strep is common in pregnant women and rarely causes any problems. Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. FRes Konto-Ghiorghi, Y. Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae.
Krishnan, V. Structure 15, — Lachenauer, C. Lamagni, T. Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, Lamy, M. Lancefield, R. But not identical, type-specific substances. Landwehr-Kenzel, S. Interaction of Streptococcus agalactiae and cellular innate immunity in colonization and disease.
Lartigue, M. Identification of Streptococcus agalactiae isolates from various phylogenetic lineages by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Lauer, P. Genome analysis reveals pili in Group B Streptococcus. Science Lazzarin, M. Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST strain. BMC Microbiol. Le Doare, K.
An overview of global GBS epidemiology. Vaccine 31 Suppl. Breast milk and Group B streptococcal infection: vector of transmission or vehicle for protection? Vaccine 32, — Lemire, P. Role of capsular polysaccharide in Group B Streptococccus interactions with dendritic cells.
Leroux-Roels, G. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
Vaccine 34, — Lewis, K. Persister cells and the riddle of biofilm survival. Biochemistry 70, — Libster, R. Long-term outcomes of group B streptococcal meningitis. Pediatrics , e8—e Lin, F. III, Azimi, P. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.
III, Clark, P. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. Lin, H. Clonal dissemination of invasive and colonizing clonal complex 1 of serotype VI group B Streptococcus in central Taiwan.
Lindahl, G. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Luan, S. Gene , — Multilocus sequence typing of Swedish invasive group B streptococcus isolates indicates a neonatally associated genetic lineage and capsule switching. Madhi, S. Prospects for preventing infant invasive GBS disease through maternal vaccination.
Vaccine 35, — Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Madoff, L. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein.
Maione, D. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Maisey, H. Recent advances in understanding the molecular basis of group B streptococcus virulence.
Group B streptococcal pilus proteins contribute to adherence to and invasion of brain microvascular endothelial cells. A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence. Manning, S. Genotypic diversity and serotype distribution of group B streptococcus isolated from women before and after delivery.
Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. Margarit, I. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. Martins, E. Analysis of group B streptococcal isolates from infants and pregnant women in Portugal revealing two lineages with enhanced invasiveness.
Matsubara, K. Melin, P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Group B streptococcal epidemiology and vaccine needs in developed countries. Meyn, L. Rectal colonization by group B Streptococcus as a predictor of vaginal colonization. Michel, J. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity.
Mu, R. Identification of a group B streptococcal fibronectin binding protein, SfbA, that contributes to invasion of brain endothelium and development of meningitis. Nobbs, A. Streptococcus adherence and colonization. Nuccitelli, A. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections.
Paoletti, L. Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin. Park, S. CsrRS and environmental pH regulate group B streptococcus adherence to human epithelial cells and extracellular matrix.
Parker, R. Association between genotypic diversity and biofilm production in group B Streptococcus. Patras, K. Group B Streptococcus CovR regulation modulates host immune signalling pathways to promote vaginal colonization. Pezzicoli, A. Exogenous sialic acid transport contributes to group B streptococcus infection of mucosal surfaces. Pilus backbone contributes to group B Streptococcus paracellular translocation through epithelial cells. Phares, C.
Epidemiology of invasive group B streptococcal disease in the United States, JAMA , — Rajagopal, L. Understanding the regulation of group B streptococcal virulence factors.
Future Microbiol. Rato, M. Antimicrobial resistance and molecular epidemiology of streptococci from bovine mastitis. Rinaudo, C. Specific involvement of pilus type 2a in biofilm formation in group B Streptococcus. Rosenau, A. Evaluation of the ability of Streptococcus agalactiae strains isolated from genital and neonatal specimens to bind to human fibrinogen and correlation with characteristics of the fbsA and fbsB genes.
Rosini, R. Biofilm formation by Streptococcus agalactiae : influence of environmental conditions and implicated virulence factors. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae.
Rubens, C. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Russell-Jones, G. A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen. Salloum, M. Diversity of prophage DNA regions of Streptococcus agalactiae clonal lineages from adults and neonates with invasive infectious disease. Santi, I. CsrRS regulates group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine development.
BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood. Schrag, S. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Schubert, A. The fibrinogen receptor FbsA promotes adherence of Streptococcus agalactiae to human epithelial cells.
Schuchat, A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Seepersaud, R. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Seifert, K. A unique serine-rich repeat protein Srr-2 and novel surface antigen epsilon associated with a virulent lineage of serotype III Streptococcus agalactiae.
Microbiology , — Sendi, P. Invasive group B Streptococcal disease in non-pregnant adults : a review with emphasis on skin and soft-tissue infections. Infection 36, — Seo, H. Characterization of fibrinogen binding by glycoproteins Srr1 and Srr2 of Streptococcus agalactiae. Binding of glycoprotein Srr1 of Streptococcus agalactiae to fibrinogen promotes attachment to brain endothelium and the development of meningitis.
Shabayek, S. Serotype and surface protein gene distribution of colonizing group B streptococcus in women in Egypt. Sheen, T. Links with this icon indicate that you are leaving the CDC website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. You will be subject to the destination website's privacy policy when you follow the link.
0コメント